Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved atezolizumab (Tecentriq) combined with chemotherapy as adjuvant treatment for stage III mismatch repair–deficient (dMMR) colon cancer in adults and children as young as 2. Data from the phase 3 ATOMIC trial showed the combo cut the risk of disease recurrence or death in half compared to chemo alone. A subcutaneous formulation was also approved for patients 12 and older weighing at least 40 kg.
The FDA has approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin (mFOLFOX6) for the adjuvant treatment of stage III mismatch repair–deficient (dMMR) colon cancer in adults and pediatric patients aged 2 and older. A subcutaneous formulation (Tecentriq Hybreza) was simultaneously approved for patients 12 and older weighing at least 40 kg — expanding access to a less invasive delivery option.
The approval was backed by the phase 3 ATOMIC trial, which enrolled patients with completely resected stage III dMMR colon adenocarcinoma, including those with Lynch syndrome. Patients received atezolizumab plus mFOLFOX6 for 12 cycles, followed by atezolizumab monotherapy for 13 additional cycles, or mFOLFOX6 alone.
By the Numbers:
Why it matters: dMMR colon cancer is a biologically distinct subtype with high immunotherapy sensitivity. This approval gives oncologists a meaningful new adjuvant option that significantly improves disease-free survival — potentially reducing recurrence rates in a population that previously had limited post-surgical treatment choices.
